← boardnext 2026-11-30next 2026-12-01
RNAC
Cartesian Therapeuticsdistress 3/10 · well-funded / low risk$7.93-2%today-42% from 52w high
Neurology 1Oncology 1
Lead: generalized myasthenia gravis · target BCMA
Revenue
pre-revenue
Liquidity
$119M
Runway
1.6 yrs
Shares 1y
+13%
Price & events
+4.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.5%
1D
-4.8%
1W
-22.1%
1M
+13.8%
3M
+3.8%
6M
-40.8%
1Y
-53.4%
2Y
-92.4%
5Y
-91.2%
All
Overview
- Market Cap
- $233.00M
- Volume
- 4.98K
- 52 Week Range
- $5.84 – $13.70
- Total Shares
- 29.38M
- Float Shares
- 10.63M
- Short %
- 14.51%
- % Held by Insiders
- 53.68%
- % Held by Institutions
- 25.18%
- RVOL
- 0.02x
- Beta
- 0.46
Pipeline stages · 2 programs
Decartes-08
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Descartes-08
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-30 Estimated 50% readout ~2027-02-13 | Phase 3 | Decartes-08 | Myasthaenia Gravis | — | recruiting |
| 2026-12-01 Estimated 50% readout ~2027-01-15 | Phase 2 | Descartes-08 | Systemic Lupus Erythematosus (SLE) | — | active not recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | Descartes-08 | Antisynthetase Syndrome | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | Descartes-08 | Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis | — | recruiting |
| 2025-07-31 | Phase 2 | Descartes-08 | Myasthenia Gravis, Generalized | 30 | active not recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-04-14 | Phase 1 | Descartes-15 | Refractory Multiple Myeloma, Relapsed Multiple Myeloma | 4 | terminated |
Catalyst news & presentations · 12
- 1H 2027Guided 55%readoutPhase 1Descartes-08 · Clinical data from Phase 1 study of in vivo CAR-T.SEC 8-K
- First Quarter 2027Guided 70%readoutTopline data from the Phase 3 AURORA trialPR wire
- 2H 2026Guided 55%trial initiationsecondaryPhase 1Descartes-08 · Phase 1 dose-escalation study of mRNA from Descartes-08 via WestGene's tLNP in MG patients.SEC 8-K
- 2026-08-06earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 2Descartes-08 · Plan to initiate randomized, placebo-controlled Phase 2 trial in myositisSEC 8-K
- 2026-06-09partnershipStrategic licensing agreement with WestGene Biopharma for in vivo CAR-T development.SEC 8-K
- 2026-05-26partnershipSecures up to $150 million of non-dilutive financing from K2 HealthVenturesPR wire
- 2026-05-26partnershipSecured up to $150 million of non-dilutive financing from K2 HealthVenturesPR wire
- by the end of 2025regulatory submissionFiled (NDA/BLA)Descartes-08 · Plan to file IND for Phase 2 myositis trialSEC 8-K
- 2025-05-30trial initiationsecondaryPhase 3Descartes-08 · First patient enrolled in Phase 3 AURORA trialSEC 8-K
- 2025-04-08safety signalDescartes-08 · No new AEs, no CRS, no ICANS, well-tolerated through Month 12SEC 8-K
- 2025-01-27spaDescartes-08 · FDA agreed under SPA to overall design of Phase 3 AURORA trial in myasthenia gravisSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $35 (+336% upside) · 7 analysts
- 2026-06-10WedbushOutperform
- 2026-06-09BTIGBuy
- 2026-06-09NeedhamBuy
- 2026-05-27WedbushOutperform
- 2026-05-26NeedhamBuy
- 2026-05-12HC Wainwright & Co.Buy
Competitors — BCMA
Recent news
- 2026-07-22JPMorgan Chase & Co. (RNAC) discloses 4.8% beneficial stake in Cartesian Therapeutics - Stock Titan
- 2026-07-14Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
- 2026-07-12Cartesian Therapeutics Inc (RNAC) - MSN
- 2026-07-12How (RNAC) Movements Inform Risk Allocation Models - Stock Traders Daily
- 2026-07-10Cartesian Therapeutics : RNAC - 24/7 Wall St.
- 2026-07-09Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme - Barchart.com
- 2026-07-09Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme - Barchart.com
- 2026-07-03RNAC Q1 2026 Earnings: Wider Loss as Pipeline Progress Continues - Consensus Beat Rate - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.